Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

λ Light Chain Bias Associated With Enhanced Binding and Function of Anti-HIV Env Glycoprotein Antibodies.

Sajadi MM, Farshidpour M, Brown EP, Ouyang X, Seaman MS, Pazgier M, Ackerman ME, Robinson H, Tomaras G, Parsons MS, Charurat M, DeVico AL, Redfield RR, Lewis GK.

J Infect Dis. 2016 Jan 1;213(1):156-64. doi: 10.1093/infdis/jiv448. Epub 2015 Sep 7.

2.

HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A, Nappi F, Longo O, Bellino S, Picconi O, Fanales-Belasio E, Borsetti A, Toschi E, Schiavoni I, Bacigalupo I, Kan E, Sernicola L, Maggiorella MT, Montin K, Porcu M, Leone P, Leone P, Collacchi B, Palladino C, Ridolfi B, Falchi M, Macchia I, Ulmer JB, Buttò S, Sgadari C, Magnani M, Federico MP, Titti F, Banci L, Dallocchio F, Rappuoli R, Ensoli F, Barnett SW, Garaci E, Ensoli B.

PLoS One. 2012;7(11):e48781. doi: 10.1371/journal.pone.0048781. Epub 2012 Nov 13.

3.

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.

J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.

4.

Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.

Mikell I, Stamatatos L.

PLoS One. 2012;7(11):e49610. doi: 10.1371/journal.pone.0049610. Epub 2012 Nov 13.

5.

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.

Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC.

J Virol. 2014 Nov;88(21):12623-43. doi: 10.1128/JVI.01705-14. Epub 2014 Aug 20.

7.

[Identification of Env-specific monoclonal antibodies from Chinese HIV-1 infected person by B cell activation and RT-PCR cloning].

Wang HM, Xu K, Yu SQ, Ding LL, Luo HY, Flinko R, Lewis GK, Feng X, Shao JR, Guan YJ, Zeng Y.

Bing Du Xue Bao. 2012 Jun;28(4):358-65. Chinese.

PMID:
22978159
8.

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, Correnti C, Johnsen W, Kegel R, Stuart AB, Glenn J, Seaman MS, Schief WR, Strong RK, Nussenzweig MC, Stamatatos L.

Nat Commun. 2016 Feb 24;7:10618. doi: 10.1038/ncomms10618.

10.

9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.

Kobie JJ, Alcena DC, Zheng B, Bryk P, Mattiacio JL, Brewer M, Labranche C, Young FM, Dewhurst S, Montefiori DC, Rosenberg AF, Feng C, Jin X, Keefer MC, Sanz I.

PLoS One. 2012;7(4):e35356. doi: 10.1371/journal.pone.0035356. Epub 2012 Apr 18.

11.

Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency.

Haim H, Salas I, McGee K, Eichelberger N, Winter E, Pacheco B, Sodroski J.

Cell Host Microbe. 2013 Nov 13;14(5):547-58. doi: 10.1016/j.chom.2013.10.006.

12.

Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection.

Jin S, Ji Y, Wang Q, Wang H, Shi X, Han X, Zhou T, Shang H, Zhang L.

Retrovirology. 2016 Feb 17;13:12. doi: 10.1186/s12977-016-0243-3.

13.

CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.

Sapsutthipas S, Tsuchiya N, Pathipavanich P, Ariyoshi K, Sawanpanyalert P, Takeda N, Isarangkura-na-ayuthaya P, Kameoka M.

PLoS One. 2013;8(1):e53920. doi: 10.1371/journal.pone.0053920. Epub 2013 Jan 7.

14.

Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier.

Domm W, Brooks L, Chung HL, Feng C, Bowers WJ, Watson G, McGrath JL, Dewhurst S.

Vaccine. 2011 Sep 16;29(40):7080-9. doi: 10.1016/j.vaccine.2011.07.008. Epub 2011 Jul 27.

15.

Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).

Killick MA, Grant ML, Cerutti NM, Capovilla A, Papathanasopoulos MA.

Vaccine. 2015 Nov 17;33(46):6298-306. doi: 10.1016/j.vaccine.2015.09.056. Epub 2015 Oct 1.

PMID:
26432912
16.

Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Malherbe DC, Pissani F, Sather DN, Guo B, Pandey S, Sutton WF, Stuart AB, Robins H, Park B, Krebs SJ, Schuman JT, Kalams S, Hessell AJ, Haigwood NL.

J Virol. 2014 Nov;88(22):12949-67. doi: 10.1128/JVI.01812-14. Epub 2014 Sep 10.

17.

The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.

Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, Montefiori DC, Meshnick SR, Swanstrom R.

J Virol. 2011 Aug;85(16):8253-62. doi: 10.1128/JVI.00197-11. Epub 2011 May 18.

18.

Broadly neutralizing antibodies against HIV-1: templates for a vaccine.

van Gils MJ, Sanders RW.

Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Review.

19.

Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates.

Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S.

J Virol. 2011 May;85(10):4927-36. doi: 10.1128/JVI.00081-11. Epub 2011 Mar 16.

Supplemental Content

Support Center